Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Reliance Global Group, Inc.
EZRA
$3.90 (+ $0.02 + 0.52%)
Last updated: Previous Close (2026-05-20)
About the Company
Reliance Global Group, Inc. is a diversified InsurTech company that leverages artificial intelligence and cloud-based technologies to transform the traditional insurance agency model. Headquartered in Lakewood, New Jersey, and founded in 2013, it operates through its RELI Exchange platform, which employs proprietary automation and AI tools to enhance productivity for agency partners in wholesale and retail insurance sectors. The company pursues growth via organic expansion of its agency partner network, introduction of new product offerings, and strategic acquisitions of high-growth insurance-related businesses. With approximately 64 employees led by CEO Ezra S. Beyman, Reliance Global Group, Inc. focuses on disrupting conventional insurance markets by integrating advanced technology solutions. Its role in the financial landscape underscores the evolving integration of fintech innovations within the insurance industry, enabling more efficient operations and scalable services for partners and clients alike.
Price History
Latest News for EZRA
Reliance Global Group Announces Reverse Stock Split
LAKEWOOD, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (“Reliance”, “we” or the “Company”) today announced that the Company’s Board of Directors approved a 1-for-40 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”) in order to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (Rule 5550(a)(2)). The Company was not required to obtain shareholder appro
Reliance Global Group Reports First Quarter 2026 Results and Advances Scale51 Strategy Through Targeted Technology and Life Sciences Investments
Company Expands Ownership-Driven Investment Model While Maintaining Insurance and InsurTech Operating Foundation Company to Host Conference Call Today at 4:30 PM Eastern Time LAKEWOOD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today reported financial results for the three months ended March 31, 2026, and provided an update on the continued execution of its Scale51 strategy through targeted investments in te
Reliance Global Group Schedules First Quarter 2026 Financial Results and Business Update Conference Call
Lakewood, NJ, May 06, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ: EZRA) (“Reliance” or the “Company”), announced today that it will host a conference call Thursday, May 7, 2026, at 4:30 PM Eastern Time to discuss financial results for the first quarter 2026 and provide a business update. The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 943560. A webcast
Reliance Global Group Launches LifeSci Global, Its Dedicated Life Sciences Platform, Partnering with Proven Operators Scott Korman and David Turner to Build and Lead the Platform with Innervate Radiopharmaceuticals as the First Platform Investment
LifeSci Global Launches as Reliance’s Life Sciences Platform, Partnering with Scott Korman and David Turner as Its Founding Operator-Partners to Build, Lead and Grow the Platform Korman and Turner Bring Complementary Decades of Private Equity, Capital Markets, Healthcare and Company-Building Expertise to Anchor the Platform; Innervate Provides Exposure to Estimated $250 Million Neuroblastoma Opportunity, Potential Expansion Opportunities in Additional Disease Areas and Priority Review Voucher Up
Reliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA’s Biotech Division
Transaction Expands EZRA International Group’s Biotech Division, LifeSci Global, Into Late-Stage Radiopharmaceutical Imaging Initial Neuroblastoma Opportunity of Approximately $250 Million, with Additional Potential Billion-Dollar Expansion Markets and Priority Review Voucher Upside LAKEWOOD, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced that LifeSci Global Group LLC (“LifeSci Global”), the biote
Reliance Global Group Increases Ownership in Enquantum to 29% Following Achievement of Defined Technical and Commercial Milestones
EZRA’s Scale51 Model Continues Advancing Path Toward Majority Control of Post-Quantum Cybersecurity PlatformLAKEWOOD, NJ, April 28, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced it has increased its ownership in Enquantum Ltd. (“Enquantum”), a developer of next-generation post-quantum cryptographic solutions. Following Enquantum’s completion of defined technical and commercial milestones, the Company funded th